Lesson plan

AOP-208

AOP-208, also known as LB-208, is a selective serotonin 5-HT 1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes. It is taken orally. The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech. As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes. The chemical structure of AOP-208 does not yet appear to have been disclosed.

Back to article

Article summary

AOP-208, also known as LB-208, is a selective serotonin 5-HT 1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes. It is taken orally. The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech. As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes. The chemical structure of AOP-208 does not yet appear to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.